Figure 4.
Effect of ECP therapy on alloreactive T cells. (A) Schematic diagram of the in vitro alloreaction model. (B) Representative histogram and dot plot of proliferation of responder cells in the alloreaction model. (C) Representative dot plot of activation status of responder cells in the alloreaction model. (D) Statistical analysis of proliferation of responder cells. (E) Statistical analysis of activation of responder cells. Samples of 3 individual donors were tested for proliferation and activation assays. (F) Cytokine profile in the supernatant of alloreaction model over time. CAR-T cells with and without ECP as stimulatory cells derived from 2 individual donors were used to stimulate allo-PBMCs derived from another 3 HLA-A2 mismatched donors. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.

Effect of ECP therapy on alloreactive T cells. (A) Schematic diagram of the in vitro alloreaction model. (B) Representative histogram and dot plot of proliferation of responder cells in the alloreaction model. (C) Representative dot plot of activation status of responder cells in the alloreaction model. (D) Statistical analysis of proliferation of responder cells. (E) Statistical analysis of activation of responder cells. Samples of 3 individual donors were tested for proliferation and activation assays. (F) Cytokine profile in the supernatant of alloreaction model over time. CAR-T cells with and without ECP as stimulatory cells derived from 2 individual donors were used to stimulate allo-PBMCs derived from another 3 HLA-A2 mismatched donors. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal